Take-private transactions are dominating PE dealmaking in 2025. Sycamore Partners took Walgreens Boots Alliance private for $23.7 billion. Blackstone and TPG agreed to acquire Hologic for up to $18.3 billion. The $55 billion acquisition of Electronic Arts made headlines globally. And Pershing Square's offer for Universal Music Group — valued at roughly $64.3 billion — pushed the boundaries of what a take-private-adjacent deal even looks like.
These are not ordinary buyouts. And the commercial due diligence that supports them shouldn't be ordinary either.
If you're on a PE deal team evaluating a take-private, you face a specific set of constraints and risks that don't apply to a typical founder-led carve-out or sponsor-to-sponsor transaction. This guide walks through what's different, what to prioritise, and how to structure primary research that actually gives you conviction before you sign.
Why CDD for a Take-Private Is Fundamentally Different
On the surface, commercial due diligence looks the same regardless of deal type: you're trying to understand the target's market, customers, competitors, and revenue durability. But take-privates introduce several dynamics that change how you need to run the process.
1. You're buying a company the market already "knows"
Public companies have analyst coverage, quarterly earnings, and years of disclosed financials. That sounds like an advantage — and it is, for financial diligence. But it creates a trap for commercial diligence: deal teams often assume the market's view of the company is accurate and skip the deep primary work. It isn't, and they shouldn't.
Sell-side analysts cover revenue trends and margins. They rarely have a ground-level view of customer satisfaction, competitive switching dynamics, or whether the company's market share is actually defensible. That's the gap CDD needs to fill.
2. Limited management access pre-LOI
In a typical PE buyout of a private company, you often get direct management presentations, data room access, and Q&A sessions during the diligence phase. In a take-private — especially a hostile or unsolicited offer — management access can be restricted or non-existent until late in the process. Sometimes you're building your entire commercial thesis from the outside in.
This makes primary research with external experts, customers, competitors, and channel partners not just useful but essential. It may be your only source of ground truth.
3. The deal clock is brutal
Take-privates involve public-market mechanics: tender offers, proxy fights, regulatory approvals, and competing bids. Timelines are compressed and often unpredictable. You may have weeks, not months, to build conviction on whether the target's commercial position justifies the premium you're paying.
This means your CDD process needs to be designed for speed from day one — pre-scoped questions, rapid expert sourcing, and parallel workstreams rather than sequential phases.
4. You're paying a control premium — so the bar for conviction is higher
Take-private premiums typically range from 30% to 50% above the unaffected share price. You're not buying at market — you're betting that the company is worth meaningfully more than what the public market says. CDD has to directly address whether the commercial fundamentals support that premium, or whether you're overpaying for a business with undisclosed competitive vulnerabilities.
The Five CDD Questions That Matter Most in a Take-Private
Every deal is different, but take-privates consistently come down to five commercial questions. Your primary research programme should be structured around answering them.
Question 1: Is the revenue base actually durable?
Public companies report revenue, but they don't always disclose the texture behind it. You need to understand:
- Customer concentration risk — Are the top 10 customers locked in or at risk of switching? What does contract renewal behaviour actually look like?
- Revenue quality — How much is recurring vs. one-off? How much is organic vs. acquisition-driven? What's the trajectory of net revenue retention?
- Pricing power — Can the company push through price increases post-acquisition, or is it already at the ceiling of what the market will bear?
How to research it: Customer interviews and B2B surveys are the fastest way to gauge stickiness and satisfaction. Talk to 10–15 current customers across segments and ask about satisfaction, likelihood to renew, competitive alternatives they've evaluated, and how they'd react to a price increase. Supplement with former sales leaders who can speak to win/loss trends and pipeline quality.
Question 2: What does the competitive landscape actually look like?
Public filings list competitors, but they don't tell you who's gaining share, who's undercutting on price, or where the disruptive threats are coming from. You need a ground-level view.
- Who is the target losing deals to, and why?
- Are there emerging competitors or substitute products that could erode the target's position over your hold period?
- How do customers and industry participants perceive the target's competitive moat — is it brand, switching costs, distribution, technology, or something else?
How to research it: Competitor interviews (former employees at rival companies), industry expert calls (consultants, analysts, channel partners), and customer surveys that include competitive benchmarking questions. Ask customers to rank the target against alternatives on the dimensions that matter: product quality, support, price, innovation.
Question 3: What's the real market size and growth trajectory?
Every public company's investor presentation shows a large and growing TAM. Your job is to pressure-test it.
- Is the TAM defined in a way that's relevant to the target's actual addressable market, or is it inflated?
- What are the real growth drivers — and are they structural or cyclical?
- Are there regulatory, demographic, or technological tailwinds (or headwinds) that the public market is mispricing?
How to research it: Expert interviews with industry veterans, former executives at the target, and adjacent market participants. Combine with a focused survey of potential buyers in under-penetrated segments to gauge realistic demand levels. Cross-reference against secondary data, but don't anchor to it.
Question 4: What's the value creation opportunity post-acquisition?
Take-privates often involve a thesis that the company is being run sub-optimally as a public entity. The commercial angle here is critical:
- Are there pricing levers the current management isn't pulling because of public-market scrutiny?
- Are there cross-sell or upsell opportunities being left on the table?
- Could go-to-market be restructured — new channels, new geographies, new customer segments — without the constraints of quarterly earnings pressure?
- Are there adjacencies or bolt-on opportunities that a PE owner could pursue more aggressively?
How to research it: Former executives of the target are invaluable here — they know where the bodies are buried and which growth levers management discussed internally but never actioned. Pair with customer interviews to validate whether the demand exists for expanded offerings.
Question 5: What are the risks the public market doesn't see?
The public market prices in known risks. Your edge comes from identifying the risks it doesn't see, or is underweighting:
- Customer churn that hasn't shown up in reported numbers yet
- A major contract renewal that's actually at risk
- A competitor product launch that could disrupt the market in 12–18 months
- Regulatory changes that are likely but not yet priced in
- Cultural or organisational issues that will create integration headaches
How to research it: This is where broad-based expert outreach earns its keep. Channel partners, former employees, industry consultants, and procurement buyers at key accounts can all surface risks that don't appear in public filings. Structure your interviews to specifically probe for "what would concern you about this business over the next three years?"
How to Structure a Take-Private CDD Programme in Practice
Here's a practical framework for running CDD on a take-private target when timelines are tight and management access is limited.
Phase 1: Pre-LOI Scoping (Days 1–3)
Before you commit resources, define the critical unknowns. Build a hypothesis map: what do you believe about this business, and what primary research would confirm or kill each assumption?
- Review public filings, earnings transcripts, and sell-side research to identify what's already known
- Identify the 3–5 commercial questions that will drive your investment decision
- Design your expert interview discussion guides and survey instruments around those questions
- Begin sourcing experts immediately — former executives, customers, competitors, and channel partners
Phase 2: Rapid Primary Research (Days 3–14)
Run multiple research workstreams in parallel, not sequentially:
- Expert interviews (8–15 calls): Former target executives, competitors, industry experts, and channel partners. Focused on competitive dynamics, market outlook, and operational realities.
- Customer research (10–20 interviews or survey responses): Current and former customers to validate revenue quality, satisfaction, and switching risk.
- Channel checks (5–10 touchpoints): Distributors, resellers, procurement teams, and other channel participants to gauge demand trends and competitive shifts.
The goal is to have synthesised findings — not raw transcripts — within two weeks. You need actionable insights, not a stack of call notes that someone on the deal team has to read at 2 AM.
Phase 3: Synthesis and Decision Support (Days 12–17)
Consolidate findings into a commercial assessment that directly maps to the investment thesis:
- Does the primary research support or challenge the revenue durability assumption?
- Is the competitive position as strong as the market believes?
- Are the value creation levers real and actionable?
- What are the commercial risks that need to be reflected in the model or negotiated into the price?
This output should feed directly into IC memos and pricing discussions — not sit in a separate research report that nobody reads.
Common Mistakes PE Teams Make on Take-Private CDD
Having supported hundreds of commercial diligence processes, we see the same mistakes repeatedly on take-private deals:
- Over-relying on public data. Just because the company files 10-Ks doesn't mean you understand its commercial position. Public data tells you what happened. Primary research tells you why — and what's likely to happen next.
- Starting expert sourcing too late. On a take-private, the clock starts ticking the moment the deal becomes public. If you wait until confirmatory diligence to start sourcing experts, you've already lost days you can't get back.
- Running CDD like a checkbox exercise. Hiring a consulting firm to produce a 150-page market study is not the same as answering the specific commercial questions that will determine whether you bid, what you bid, and how you structure the deal. Every hour of primary research should be aimed at a decision.
- Not talking to customers directly. Some deal teams avoid customer research because they're worried about tipping off the market. That's a legitimate concern — but it's manageable with proper design. Blind surveys, third-party-conducted interviews, and careful sampling can get you the customer insight you need without compromising deal confidentiality.
- Treating the CDD provider as a transcription service. If your team is scheduling its own expert calls, writing its own discussion guides, and synthesising its own transcripts, you're spending deal-team hours on research operations instead of deal judgment. That's a misallocation, especially on a compressed timeline.
Why Speed and Depth Aren't Trade-Offs — If You Have the Right Research Partner
The fundamental tension on any take-private CDD is time versus depth. You need to understand the commercial dynamics of a complex public company in a fraction of the time you'd normally have. Most deal teams resolve this tension by sacrificing depth — they do fewer expert calls, skip customer research, or rely more heavily on secondary sources.
That's the wrong trade-off. The premium you're paying on a take-private makes commercial risk the most expensive thing to get wrong.
The right approach is to work with a research partner that can run the full primary research programme — expert interviews, customer surveys, channel checks — end-to-end and deliver synthesised, decision-ready findings within the deal timeline. Not a platform where your associates book calls. Not a network where you get names and figure out the rest. A team that takes a brief, runs the research, and hands back answers.
That's what we do at Woozle Research. We've supported commercial due diligence on take-privates across software, healthcare, industrials, consumer, and financial services. We know how to work within deal timelines, maintain confidentiality, and deliver research that directly supports investment committee decisions.
